...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: RVXOT

KOO - Regardless of what we think, I believe that is how it is. If I remember correctly, the RPS are owned by ZCC which makes them the property of all ZCC shareholders, not just the shareholders at time of company split. It is fair if there is enough built into the share price of any newly issued shares to cover the value of the RPS but how do we judge that?

Share
New Message
Please login to post a reply